Biliopancreatic malignancy: Future prospects for progress

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Ho, Jenny J L ^a   Kim, Young S ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Immunotherapy; Risk factors; Signal transduction

Indexed keywords

GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MUCIN; NUCLEIC ACID; TUMOR ANTIGEN; TUMOR VACCINE;

ANGIOGENESIS; BILE DUCT CANCER; CANCER RISK; CELL GROWTH; CONFERENCE PAPER; EARLY DIAGNOSIS; GENE MUTATION; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

EID: 0032784001     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S300     Document Type: Conference Paper

References (77)

1. Homma, T., Tsuchiya, R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints of icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int. J. Pancreatol. 9:119-24, 1991.
2. Moskaluk, C.A., Hruban, R.H., Schutte, M. et al. Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma. Diag. Mol. Path. 6: 85-90, 1997.
3. Dergham, S.T., Dugan, M.C., Arlauskas, P. et al Relationship of family cancer history to the expression of p53, p21WAF-1. HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. Int. J. Pancretol. 21:225-34, 1997.
4. Lumadue, J.A., Griffin, C.A., Osman, M. et al Familial pancreatic cancer and the genetics of pancreatic cancer. Surg. Clin. North America 75:845-55, 1995.
5. Gold, E.B., Goldin, S.B. Epidemiology of and risk factors for pancreatic cancer. Surg. Oncol. Clinics North America 7:67-91, 1998.
6. Karlson, B.M., Wuu, J., Hsieh, C.C. et al Parity and risk of pancreatic cancer: a nested case-control study. Int. J. Cancer 77:224-7, 1998.
7. Flanders, T.Y., Foulkes, W.D. Pancreatic adenocarcinoma: Epidemiology and genetics. J. Med. Gen. 33:889-98, 1996.
8. Harnack, I.J., Anderson, K.E., Zheng, W. et al Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Women's Health Study. Cancer Epidem., Biomarkers, Prevention 6:1081-6, 1997
9. Chatenoud, L., Tavani, A., La Vecchia, C. et al Whole grain food intake and cancer risk. Int. J. Cancer 77:24-8, 1998.
10. Steinmetz, KA, Potter, JD. Vegetables, fruit, and cancer prevention: A review. J. Amer. Diet. Assn. 96:1027-39, 1996.
11. Ji, B.T., Chow, W.H., Hsing, A.W. et al Green tea consumption and the risk of pancreatic and colorectal cancers. Int. J. Cancer 70:255-8, 1997.
12. Ho, J.J.L. Mucin-associated carbohydrate biomarkers in early pancreatic cancer. Int. J. Pancreatol. 16:254-7, 1994.
13. Ritts, R.E., Pitt, H.A. CA19-9 in pancreatic cancer. Surg. Oncol. Clin. North America 7:93-101, 1998.
14. Ho, J.J.L., Kim, Y.S. Serological pancreatic tumor markers and the MUC1 apomucin. Pancreas 9:674-91, 1994.
15. Terada, T., Ohta, T., Sasaki, M. et al Expression of MUC apomucins in normal pancreas and pancreatic tumours. J. Path. 180:160-5, 1996.
16. Gum, J.R., Jr., Ho, J.J.L., Pratt, W.S. et al MUC3 human intestinal mucin. Analysis of gene structure, the carboxyl terminus, and a novel upstream repetitive region. J. Biol. Chem. 272:26678-86, 1997.
17. Almoguera, C., Shibata, D., Forrester, K. et al Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-54, 1988.
18. Cerny, W.L., Mangold, K.A., Scarpelli, D.G. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Can. Res. 52:4507-13, 1992.
19. Schaeffer, B.K., Glasner, S., Kuhlmann, E. et al Mutated c-K-ras in small pancreatic adenocarcinomas. Pancreas 9:161-5, 1994.
20. Moskaluk, C.A., Hrubun, R.H., Kern, SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Can. Res. 57:2140-3, 1997.
21. Ito, R., Tamura, K., Ashida, H. et al Usefulness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. Int. J. Oncol. 12:1019-23, 1998.
22. Tada, M., Omata, M., Kawai, S. et al Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic denocarcinoma. Can. Res. 53:2472-4, 1993.
23. Caldas, C., Hahn, S.A., Hruban, R.H. et al Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Can. Res. 54:3568-73, 1994.
24. Wilentz, R.E., Chung, C.H., Sturm, P.D. et al K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 82:96-103, 1998.
25. Wanebo, H.J., Vezeridis, M.P. Pancreatic carcinoma in perspective. A continuing challenge. Cancer 78:580-91, 1996.
26. Pluda, J.M., Parkinson, D.R. Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer 78: 680-7, 1996.
27. Weidner, N., Semple, J.P., Welch, W.R. et al Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. New Engl. J. Med. 324:1-8, 1991.
28. Korc, M., Chandrasekar, B., Yamanaka, Y. et al Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest. 90:1352-60, 1992.
29. Yamanaka, Y., Friess, H., Kobrin, M.S. et al Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Path. 24:1127-37, 1993.
30. Scarpa, A., Capelli, P., Mukai, K. et al Pancreatic adenocarcinomas frequently show p53 gene mutations. Amer. J. Path. 142:1534-43, 1993.
31. Ho, J.J.L., Kim, Y.S. Do mucins promote tumor cell metastasis? Int. J. Oncol. 7:913-926, 1995.
32. Iruela-Arispe, M.L., Dvorak, H.F. Angiogenesis: A dynamic balance of stimulators and inhibitors. Thromb. Haem. 78:672-7, 1997.
33. Claffey, K.P., Brown, L.F., del Aguila, L.F. et al Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metasasis. Can. Res. 56:172-81, 1996.
34. Kong, H., Crystal, R. Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst. 90:273-86, 1998.
35. Asano, M., Yukita, A., Matsumoto, T. et al Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Can. Res. 55:5296-301, 1995.
36. O'Reilly, M.S., Boehm, T., Shing, Y. et al Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-85, 1997.
37. Sim, BK, O'Reilly, M.S., Liang, H. et al A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Can. Res. 57:1329-34, 1997.
38. Yamazaki, H., Kijima, H., Ohnishi, Y. et al Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J. Natl. Cancer Inst. 90:581-887, 1998.
39. Levitzki, A., Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science 267:1782-8, 1995.
40. Fan, Z., Mendelsohn, J. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol. 10:67-73, 1998.
41. Baselga, J., Norton, L., Albanell, J. et al Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Can. Res. 58:2825-31, 1998.
42. Schmiegel, W., Schmielau, J., Henne-Bruns, Doris et al Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl. Acad Sci. USA 94:12622-26, 1997.
43. Chandler, L.A., Sosnowski, B.A., McDonald, J.R. et al Targeting tumor cells via EGF receptors: Selective toxicity of an HBEGF-toxin fusion protein. Int. J. Cancer 78:106-11, 1998.
44. Karnes, W.E., Jr., Weller, S.G., Adjei, P.N. et al Inhibition of epidermal growth factor receptor kinase induces protease-dependenl apoptosis in human colon cancer cells. Gastroent. 114:930-9, 1998.
45. Viloria Petit, A.M., Rak, J., Hung, M. et al Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Angiogenic implications for signal transduction therapy of solid tumors. Amer. J. Pathol. 151:1523-31, 1997.
46. Lemoine, N.R. Molecular advances in pancreatic cancer. Digestion 58:550-56, 1997.
47. Bouvet, M., Ellis, L.M., Nishizaki, M. et al Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Can. Res. 58:2288-92, 1998.
48. Aoki, K., Yoshida, T., Matsumoto, N. et al Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol. Carcin. 20:251-8, 1997.
49. Hwang, R.F., Gordon, E.M., Anderson, WF et al Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surg. 124:1433-150, 1998.
50. Joshi, U.S., Dergham, S.T., Chen, Y.Q. et al Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 16:107-13, 1998.
51. Kainuma, O., Asano, T., Hasegawa, M. et al Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas 15:379-83, 1997.
52. Gjertsen M.K., Bakka, A., Breivik, J. et al Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346:1399-1400, 1995.
53. DeLeo, A.B. p53-based immunotherapy of cancer. Crit. Rev. Immunol. 13:29-35, 1998.
54. Ychou, M. Pelegrin, A., Faurous, P. et al. Phase - I/II radio-immunotherapy study with iodine-131 labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer. Int. J. Cancer 75:615-9, 1998.
55. Jain, R.K. The next frontier of molecular medicine: Delivery of therapeutics. Nature Med. 4: 655-7, 1998.
56. Kreitman, RJ, Pastan, I. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cells are sufficient for complete responses. Can. Res. 58:968-75, 1998.
57. 131I-labeled monoclonal antibody Nd2 in xenografted nude mice. Jpn. J. Can. Res. 87:977-84, 1995.
58. Aboagye, E.O. Artemov, D., Senter, P.D. et al Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: Noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Can. Res. 58:4075-8, 1998.
59. Ho, J.J., Farrelly, E.R., Logvinova, A. et al Regulation of the pancreatic tumor antigen Nd2 hy cyclic AMP, phorbol ester, secretin and VIP. Gastroent. 112:A449, 1997.
60. Katayose, Y., Kudo, T., Suzuki, M. et al MUC1-specific targeting immunotherapy with bispecific antibodies: Inhibition of xenografted human bile duel carcinoma growth. Can. Res. 56:4205-12, 1996.
61. Shinoda, M., Kudo, T., Suzuki, M. et al Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice. Can. Res. 58:2838-2343, 1998.
62. Haga, Y., Sivinski, C.L., Woo, D. et al Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. Int. J. Pancreatol. 15:43-50, 1994.
63. Nishihara, T., Chung, Y.S., Sawada, T. et al Biological benefit of chimeric antipancreatic cancer antibody Nd2 for radioimmunotherapy. Proc. Amer. Assn. Can. Res. 38:487, 1997.
64. Miles, D.W., Towlson, K.E., Graham, R. et al A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Brit. J. Cancer 74:1292-6, 1996.
65. Goydos, J.S., Elder, E., Whiteside, T.L. et al A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63:298-304, 1996.
66. Graham, R.A., Burchell, J.M., Beverley, P. et al Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int. J. Cancer 65:664-70, 1996.
67. Pardoll, D.M. Cancer vaccines. Nature Med. 4:525-31, 1998.
68. DeMatos, P., Abdel-Wahab, Z., Vervaert, C. et al Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell. Immunol. 185:65-74, 1998.
69. Soiffer, R., Lynch, T., Mihm, M. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 95:13141-6, 1998.
70. Jaffee, E.M., Schutte, M., Gossett, J. et al Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. from Scientific American 4:194-203, 1998.
71. Esteban, J.M., Battifora, H. Tumor immunophenotype: Comparison between primary neoplasm and its metastases. Mod. Pathol. 3: 192-7, 1990.
72. Reyes, G., Villaneuva, A., Garcia, C. et al Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Can. Res., 56:5713-9, 1996.
73. Demeure, M.J., Doffek, K.M., Komorowski, R.A. et al Adenocarcinoma of the pancreas: Detection of occult metastases in regional lymph nodes by a polymerase chain reaction-based assay. Cancer 83:1328-34, 1998.
74. Noguchi, S., Aihara, T., Motomura, K. et al Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Amer. J. Pathol. 148: 649-56, 1996.
75. Kishimoto, T., Ishikura, H., Kimura, C. et al Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: The importance of surface sialyl Lewis (a) antigen. Int. J. Cancer 60:290-4, 1996.
76. Ishikawa, O., Ohigashi, H., Sasaki, Y. et al Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Amer. J. Surg. 168:361-4, 1994.
77. Yang, L., Hwang, R., Pandit, L. et al Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg. 224:405-14, 1996.